Argifin
Also known as: Argifin, GlcNAc-Arg cyclic pentapeptide
Source Argifin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Argifin is a naturally occurring cyclic pentapeptide that inhibits family‑18 chitinases. Isolated from soil‑derived fungi, it is used in research to probe chitinase function and as a lead scaffold for antifungal, insecticidal and anti‑asthma strategies. It is not an approved drug and remains a laboratory tool.
Mechanism of Action
Argifin acts as a competitive inhibitor of family‑18 chitinases by mimicking the N‑acetyl‑glucosamine substrate. Crystallographic data show it occupies the catalytic cleft and the –1 subsite, binding the catalytic machinery of bacterial‑type chitinases with nanomolar affinity, while having little effect on smaller plant‑type enzymes.
What the Research Shows
Since its isolation, Argifin has been synthesized by solid‑phase methods (overall 13% yield) and used to explore structure‑activity relationships. An acyclic analogue (18b) proved ~70‑fold more potent against Serratia marcescens chitinase B. Structural studies revealed its binding mode, guiding the design of macrolide and azamacrolide derivatives that achieve 200‑fold higher potency and nanomolar IC50 values against bacterial and insect chitinases. Bioassays demonstrated significant insect mortality (e.g., 80% at 50 mg/L against Mythimna separata). Reviews highlight its relevance for antifungal, insecticidal, and potential human chitinase‑targeted therapies.
Reported Benefits
Argifin provides a highly specific, nanomolar inhibitor of bacterial‑type family‑18 chitinases, useful for dissecting chitin metabolism in microbes, insects and fungi. Its scaffold has guided the creation of more drug‑like macrolide and azamacrolide inhibitors with improved potency and insecticidal activity, offering promising leads for agricultural pest control and, theoretically, for modulating human chitinases implicated in asthma.
Limitations of the Evidence
Evidence for Argifin is limited to in‑vitro enzyme assays, structural studies, and insect mortality tests; no animal or clinical data exist. The natural peptide is synthetically complex and unsuitable as a drug candidate without modification. Activity is selective for bacterial‑type chitinases and does not extend to plant‑type enzymes, narrowing its therapeutic scope. All reported benefits remain pre‑clinical.
Safety Considerations
No human safety or toxicity data are reported for Argifin. Insecticidal studies show mortality at 50 mg/L concentrations, indicating biological activity at relatively high doses. As a peptide, it is unlikely to be intrinsically toxic to mammals, but the absence of pharmacokinetic or adverse‑effect data warrants caution for any translational use.
How It Is Administered
Argifin is employed in laboratory settings, typically dissolved in aqueous buffers for enzymatic inhibition assays. In pest‑control research, it has been formulated as a solution or spray applied to insects at milligram‑per‑liter concentrations. No approved dosage form or route exists for human or veterinary use.
Routes of Administration
No administration routes recorded yet.
Goals & Uses
- Anti-parasitic drug developmentInfectious Disease / AntiparasiticLow
- Structural biology toolResearchHigh
- Anti-fungal drug developmentInfectious Disease / AntifungalLow
- Chitinase inhibition (family 18)Enzyme Inhibition / ResearchModerate
- Anti-asthma / allergic airway diseaseRespiratory / Anti InflammatoryLow
Contraindications
No contraindications recorded yet.
Adverse Effects
No adverse effects recorded yet.
Drug Interactions
No drug interactions recorded yet.
Population Constraints
No population constraints recorded yet.
Regulatory Status
- European UnionUnapprovedResearch compound only; no clinical approval.
- United StatesUnapprovedResearch compound only; no IND or clinical approval.
- United KingdomUnapprovedResearch compound only; no clinical approval.
Argifin has no approved clinical indications in any jurisdiction. It remains a research tool compound used in structural biology and drug discovery programs targeting chitinases.
Evidence & Sources
- Journal ArticleLowSunazuka T, et al.2009-01-01T00:00:00.000000Z
- Recent development of two chitinase inhibitors, Argifin and Argadin, produced by soil microorganismsJournal ArticleModerateHirose T, Sunazuka T, Omura S2010-01-01T00:00:00.000000Z
- Journal ArticleModerateHirose T2012-01-01T00:00:00.000000Z
- Journal ArticleLowRush CL, et al.2010-01-01T00:00:00.000000Z
- Journal ArticleLowSugawara A, et al.2015-01-01T00:00:00.000000Z
- Journal ArticleLowZhao Z, et al.2022-01-01T00:00:00.000000Z
Frequently Asked Questions
What type of enzyme does Argifin inhibit?
Argifin selectively inhibits family‑18 chitinases, especially the bacterial‑type subfamily that degrades chitin, by competitively binding the active site.
Can Argifin be used as a pesticide?
In laboratory bioassays, Argifin‑derived compounds caused high mortality in several insect pests, suggesting potential as a lead for pesticide development, but no commercial formulations are available.
Is Argifin being developed as a drug for asthma?
Human acidic mammalian chitinase is a target for asthma, and Argifin has been discussed as a research tool for this purpose, but no clinical studies or safety data have been reported.
Why is Argifin not a drug candidate itself?
The natural peptide is synthetically demanding, has limited stability, and lacks drug‑like properties; consequently, researchers modify its key pharmacophore onto more tractable scaffolds.
How is Argifin produced for research?
A solid‑phase total synthesis protocol yields Argifin in about 13 % overall yield, enabling the production of analogues for biochemical and structural studies.
What is Argifin?
Argifin is a naturally occurring cyclic pentapeptide that inhibits family‑18 chitinases. Isolated from soil‑derived fungi, it is used in research to probe chitinase function and as a lead scaffold for antifungal, insecticidal and anti‑asthma strategies. It is not an approved drug and remains a laboratory tool.
What is Argifin used for?
Argifin is educationally associated with: Anti-parasitic drug development, Structural biology tool, Anti-fungal drug development, Chitinase inhibition (family 18), Anti-asthma / allergic airway disease. Educational only — not medical advice.